SOLVNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Solventum Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$85.05−0.76 (-0.89%)
Close on Oct 19, 2026
- Market cap
- $14.74B
- P/E (TTM)
- 10.4
- Dividend yield
- –
Share price
+$12.89 (+17.86%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Solventum Corp saw revenue fall 0.9% to $8.31B over the twelve months to Jun 30, 2026. Operating income rose 167.2% to $2.08B, moving the operating margin from 9.3% to 25.0%. Free cash flow was -$118.00M, down 180.3% from a year earlier.
Revenue
$8.31B
-0.9% vs. a year earlier
Operating income
$2.08B
+167.2% vs. a year earlier
Free cash flow
-$118.00M
-180.3% vs. a year earlier
EPS, diluted
$8.18
+277.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $14.74B
- P/E ratio
- 10.4
- Price to sales
- 1.77
- Price to book
- 3.07
- Dividend yield
- –
- Free cash flow yield
- -0.80%
Fundamentals
- Revenue
- $8.31B
- Net income
- $1.43B
- EPS, diluted
- $8.18
- Free cash flow
- -$118.00M
- Book value per share
- $27.70
- Diluted shares
- 173M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
$8.31B-0.9% YoY
Gross profit
$4.55B-0.6% YoY
Operating income
$2.08B+167.2% YoY
Net income
$1.43B+277.4% YoY
EPS, diluted
$8.18+277.0% YoY
Free cash flow
-$118.00M-180.3% YoY
Reported periodTrailing twelve months